Literature DB >> 22507857

Incidental finding of monoclonal gammopathy in blood donors: a follow-up study.

Massimo La Raja1, Monica Barcobello, Nicola Bet, Paolo Dolfini, Marina Florean, Federica Tomasella, Vincenzo De Angelis, Luca Mascaretti.   

Abstract

BACKGROUND: The incidental finding of monoclonal immunoglobulin in the sera of healthy blood donors is a relatively frequent event and in such cases the subjects are commonly deferred permanently from donating blood. However, no follow-up studies of these cases have been published so far.
MATERIALS AND METHODS: Since 2000, all regular blood donors at Trieste Blood Bank have undergone annual screening by serum protein electrophoresis. Cases presenting with monoclonal gammopathy between January 2000 and December 2008 were registered and follow-up was performed until December 2010.
RESULTS: Out of 8,197 regular blood donors, monoclonal gammopathy was detected in 104 subjects (1.3%). The median age at detection was 53 years, the median monoclonal protein concentration was 0.2 g/dL and the cumulative follow-up of these cases amounted to 763 person/years. In two cases asymptomatic multiple myeloma was diagnosed within 6 months of detection of the gammopathy and in 14 cases, the monoclonal gammopathy was transient. The remaining 88 cases were classified as having monoclonal gammopathy of undetermined significance (MGUS). Out of these, two events related to monoclonal gammopathy were observed during the follow up: one lymphoma and one light chain deposition nephropathy. DISCUSSION: According to current prognostic staging systems, the majority of blood donors with monoclonal gammopathy were classified as having low-risk MGUS and had a very low incidence of lymphoproliferative diseases. Permanent deferral of blood donors with stable MGUS causes about a 1% loss of potential blood donations and it represents a "precautionary measure" that needs to be substantiated and validated.

Entities:  

Mesh:

Year:  2012        PMID: 22507857      PMCID: PMC3417733          DOI: 10.2450/2012.0083-11

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  22 in total

1.  Malignant transformation of monoclonal gammopathy of undetermined significance: cumulative incidence and prognostic factors.

Authors:  N Van De Donk; O De Weerdt; M Eurelings; A Bloem; H Lokhorst
Journal:  Leuk Lymphoma       Date:  2001-08

2.  Systematic survey of monoclonal gammapathies in the sera from blood donors.

Authors:  J M Fine; P Lambin; C Derycke; J Y Muller; M Marneux
Journal:  Transfusion       Date:  1979 May-Jun       Impact factor: 3.157

3.  MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.

Authors:  S Vincent Rajkumar
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

4.  Monoclonal gammopathies in a series of 1743 plasma donors.

Authors:  Vladimír Maisnar; Milos Tichý; Vít Rehácek; Vladimír Palicka; Jaroslav Malý
Journal:  Acta Medica (Hradec Kralove)       Date:  2006

5.  Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.

Authors:  Francesca Rossi; Maria Teresa Petrucci; Andrea Guffanti; Luigi Marcheselli; Davide Rossi; Vincenzo Callea; Federico Vincenzo; Marianna De Muro; Alessandra Baraldi; Oreste Villani; Pellegrino Musto; Andrea Bacigalupo; Gianluca Gaidano; Giuseppe Avvisati; Maria Goldaniga; Lorenzo Depaoli; Luca Baldini
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

Review 6.  The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS).

Authors:  Sumit Madan; Philip R Greipp
Journal:  Blood Rev       Date:  2009-08-20       Impact factor: 8.250

7.  Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  Clara Cesana; Catherine Klersy; Luciana Barbarano; Anna Maria Nosari; Monica Crugnola; Ester Pungolino; Livio Gargantini; Simonetta Granata; Marina Valentini; Enrica Morra
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

Review 8.  Pathogenesis and progression of monoclonal gammopathy of undetermined significance.

Authors:  J Bladé; L Rosiñol; M T Cibeira; C F de Larrea
Journal:  Leukemia       Date:  2008-07-31       Impact factor: 11.528

9.  [Transient monoclonal gammopathies. Study of 34 cases].

Authors:  P Giraldo; D Rubio-Félix; P Delgado; M Giralt
Journal:  Sangre (Barc)       Date:  1994-10

10.  Monoclonal gammopathy in Iceland: a population-based registry and follow-up.

Authors:  Helga M Ogmundsdóttir; Vilhelmína Haraldsdóttir; Guethmundur M Jóhannesson; Guethríethur Olafsdóttir; Kristín Bjarnadóttir; Helgi Sigvaldason; Hrafn Tulinius
Journal:  Br J Haematol       Date:  2002-07       Impact factor: 6.998

View more
  4 in total

1.  Acquired Fanconi syndrome due to long-term adefovir administration in a patient with IgG-kappa monoclonal gammopathy and kappa Bence-Jones protein.

Authors:  Shuzo Kaneko; Yoshiyuki Hatakeyama; Yusuke Tsukamoto
Journal:  CEN Case Rep       Date:  2014-03-14

Review 2.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

3.  Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.

Authors:  Theodóra Rún Baldursdóttir; Þorvarður Jón Löve; Gauti Kjartan Gíslason; Magnus Björkholm; Ulf-Henrik Mellqvist; Sigrun Helga Lund; Cecilie Hveding Blimark; Ingemar Turesson; Malin Hultcrantz; Ola Landgren; Sigurður Yngvi Kristinsson
Journal:  Eur J Haematol       Date:  2020-12-28       Impact factor: 3.674

4.  Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study.

Authors:  Ling Ma; Shuang Xu; Jianhua Qu; Jian Hou; Yang Wang; Lei Wen; Yang Liu; Ying Kang; Ming Jiang; Weijun Fu; Juan Du; Lin Zhou; Xiaojun Huang; Zhaoxia Zhang; Jin Lu
Journal:  Hematol Oncol       Date:  2018-10-01       Impact factor: 5.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.